Franz Bernhard Humer is a Swiss-Austrian businessman, the chairman of Diageo, and of Roche... (wikipedia)
I maintain the belief that it is not that easy or productive or value-creating going for a mega-merger,
I would say that we would see an acceleration (in drug sales), especially in the second half of the year, with the introduction of new products, with the acceleration also of the penetration of the oncology line in the non-U.S. markets,
It became a drug which was difficult to commercialize, ... We sat there with a drug in which we had invested a significant amount of development and where we had sales that were less than exciting.
It is of utmost importance to have a facility that can respond to the increasing market demand for our PCR products.
Our pharmaceuticals division gained additional market share, with all major products contributing to this strong performance, particularly our new cancer medicines,
Patents will not stand in the way of producing the drug for mankind.
We are currently assessing which organizations and countries have the ability to supplement our own capability,
This unprecedented transaction significantly strengthens our position, as it enables Roche to become a leader in the second-largest pharmaceuticals market worldwide and adds global access to Chugai's solid research and development pipeline,
We will talk to anybody -- people who can manufacture the drug, and are able to manufacture it faster than us, and complement our manufacturing,
This is because of the timing of our production capacity increase but also because that's when governments have asked for delivery.
If I look at what we have in the product pipeline, and what we have licensed in, I maintain our stance that we can manage with organic growth.
All growth drivers continued last year's strong performance.